Please try another search
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company’s ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.
Name | Age | Since | Title |
---|---|---|---|
William H. Robinson | 54 | 2011 | Director |
Franklin M. Berger | 73 | 2014 | Independent Director |
Brian G. Atwood | 69 | 2013 | Independent Chairman of the Board |
Kristine M. Ball | 50 | 2020 | Independent Director |
David Lacey | 70 | 2016 | Independent Director |
Lindsey Rolfe | 54 | 2019 | Independent Director |
Lawrence Steinman | 74 | 2019 | Chairman of External Scientific Advisory Board & Technical Advisor |
Douglas Crawford | - | - | Board Observer |
Andrew Farnum | - | - | Board Observer |
Stephen R. Brady | 52 | 2021 | Independent Director |
Stacey Ma | 51 | 2021 | Independent Director |
John A. Orwin | 58 | 2018 | President, CEO, Director & Principal Financial Officer |
Tito A. Serafini | 61 | 2010 | Founder & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review